ERS Genomics Limited and DefiniGEN Ltd announced a license agreement to provide DefiniGEN with access to ERS Genomic’s CRISPR/Cas9 genome editing technology patents
Scientists worldwide are developing new technologies and making progress toward understanding the dynamics of three-dimensional organization of the nucleus